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Amitriptyline, a tricyclic antidepressant, has been used in the clinic to treat a number of
disorders, in particular major depression and neuropathic pain. In the 1970s the ability
of tricyclic antidepressants to inhibit acid sphingomyelinase (ASM) was discovered. The
enzyme ASM catalyzes the hydrolysis of sphingomyelin to ceramide. ASM and ceramide
were shown to play a crucial role in a wide range of diseases, including cancer, cystic
fibrosis, diabetes, Alzheimer’s disease, and major depression, as well as viral (e.g.,
measles virus) and bacterial (e.g., Staphylococcus aureus, Pseudomonas aeruginosa)
infections. Ceramide molecules may act in these diseases by the alteration of membrane
biophysics, the self-association of ceramide molecules within the cell membrane and
the ultimate formation of larger ceramide-enriched membrane domains/platforms. These
domains were shown to serve the clustering of certain receptors such as CD95 and may
also act in the above named diseases. The potential to block the generation of ceramide by
inhibiting the ASM has opened up new therapeutic approaches for the treatment of these
conditions. Since amitriptyline is one of the longest used clinical drugs and side effects
are well studied, it could potentially become a cheap and easily accessible medication for
patients suffering from these diseases. In this review, we aim to provide an overview of
current in vitro and in vivo studies and clinical trials utilizing amitriptyline to inhibit ASM
and contemplate possible future applications of the drug.
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INTRODUCTION
In the past, lipids were mainly known to be important for keep-
ing cell shape. Since then, a lot of new information has changed
our understanding of lipids and awarded them with new impor-
tance. According to current knowledge lipids are involved inmany
different signaling pathways, including cell survival, prolifera-
tion, and differentiation, but also in senescence and apoptosis.
One major group of lipids involved in these pathways are the
sphingolipids. A key enzyme in the sphingolipid pathway is acid
sphingomyelinase (human: ASM, murine: Asm). This enzyme
was shown to play a crucial role in many different diseases, for
example in major depression, cancer, cystic fibrosis, and infec-
tious diseases.
In this review, we will discuss the impact of lipid domain
formation by ASM in these and other ASM-related dis-
eases and go on to discuss the potential clinical bene-
fits of inhibiting ASM in these conditions. To this end,
we will address current studies employing ASM inhibitors,
especially the functional ASM inhibitor amitriptyline, which
is already clinically used as an antidepressant. We will
critically assess the effectiveness of amitriptyline and also
point out potential new applications in therapeutic treat-
ment of diseases. Next to amitriptyline, we will also con-
sider further treatment possibilities relying on the inhibition of
ASM.
ACID SPHINGOMYELINASE
Acid sphingomyelinase is an endo-lysosomal protein of 629
amino acids and with a molecular weight of 75/72 kDa or,
after limited proteolysis during maturation, 57 kDa, respectively
(Hurwitz et al., 1994a). The enzyme catalyzes the hydrolysis of
sphingomyelin to phosphorylcholine and the second messenger
ceramide with an optimum of pH at 5.0. The importance of ASM
is evident in a lysosomal storage disorder called Niemann-Pick
disease type A and B, in which sphingomyelin accumulates in the
endo-lysosomal compartment due to ASM deficiency.
Two forms of ASM are described depending on their cellular
localization (Takahashi et al., 2005; Jenkins et al., 2009, 2010;
Milhas et al., 2010): a lysosomal ASM (L-SM) and a secretory
ASM (S-SM). The two forms result from alternative trafficking
of the precursor protein. Both forms can be distinguished by
their glycosylation status: due to the Golgi-mediated transport
to the plasma membrane, S-SM is N-glycosylated in a more
complex manner compared to L-SMase (Schissel et al., 1998).
Six glycosylation sites have been identified in the ASM protein
and deglycosylation results in inactivation of the protein (Ferlinz
et al., 1997). Further, S-SM activity depends on Zn2+ ions, L-SM
has already bound Zn2+ ions and is therefore independent of
exogenous ions (Schissel et al., 1996, 1998). In 2001, Grassmé and
coworkers demonstrated for the first time that ASM activation is
linked to translocation of the enzyme to the plasma membrane
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upon CD95 stimulation (Grassmé et al., 2001a). Since then, a
large number of studies have analyzed the regulation of lysosomal
ASM with respect to ASM translocation in combination with
ASM activation in response to different stimuli (e.g., Grassmé
et al., 2002; Abdel Shakor et al., 2004; Lacour et al., 2004; Rotolo
et al., 2005; Dumitru and Gulbins, 2006; Zeidan and Hannun,
2007; Zhang et al., 2007; Perrotta et al., 2010; Edelmann et al.,
2011; Li et al., 2012, 2013), but only a few studies have addressed
the secreted form of the enzyme (Schissel et al., 1996, 1998; Wong
et al., 2000; Jenkins et al., 2009) and these studies have been
limited to cell models, plasma, or serum (Mühle et al., 2013).
ASM can be activated by various stimuli, e.g., reactive oxygen
species, death receptors, irradiation, stress stimuli, or infections
(for overview see Table 1). Different activation mechanisms have
been described in this context. For example, ASM can be acti-
vated by phosphorylation: it has been demonstrated that protein
kinase C delta (PKCδ) phosphorylates ASM at Ser508, resulting in
immediate activation and translocation to the plasma membrane
(Zeidan and Hannun, 2007; Zeidan et al., 2008). A further mech-
anism describes the proteolytic cleavage of ASM by caspase-7,
resulting in increased activity (Edelmann et al., 2011). In addi-
tion, at least in vitro enzyme activity can be enhanced by the
modification of a free, C-terminal cysteine (Cys629) and this
activation mechanism seems to be essentially identical to the
“cysteine switch” known for metalloproteases: in the low activ-
ity form, Cys629 is involved in the active site zinc coordination,
impairing the enzymes ability for nucleophilic attack. Increased
activity results from the absence of Cys629 in the coordination of
the active site zinc atom (e.g., due to dimerization of ASM via this
cysteine), which increases catalytic effectiveness (Qiu et al., 2003).
ASM-MEDIATED FORMATION OF CERAMIDE-ENRICHED MEMBRANE
DOMAINS
In 1972 Singer and Nicolson proposed the so called “fluid mosaic
model,” describing the organization of biological membranes.
They postulated a random distribution of lipids and proteins
and the free movement of proteins within the membrane (Singer
and Nicolson, 1972). However, this proposed “fluid-disordered
status” of membranes has since been revised in favor of a
liquid-ordered model: hydrophilic and hydrophobic interactions
of lipids with each other result in lipid clustering, promoting
ordered structures within the membrane (Simons and Ikonen,
1997; Brown and London, 1998). These microdomains have been
termed lipid rafts, because they seem to float in the “ocean” of
other lipids (Simons and Ikonen, 1997; Verkade and Simons,
1997; Brown and London, 1998). Compared to most protein-
protein interactions, the interactions of lipid molecules with each
other are weak and short-lived. Nevertheless, the combination of
lipid clustering and lipid-protein interactions enables the lateral
sorting of various proteins and thus the formation of dynamic
signaling platforms.
Ceramide-enriched membrane platforms are one example of
lipid domains. Upon certain stimuli, ASM translocates from
the lysosomes and secretory lysosomes to the outer leaflet
of the plasma membrane (e.g., Grassmé et al., 2001a, 2002;
Abdel Shakor et al., 2004; Lacour et al., 2004; Rotolo et al.,
2005; Dumitru and Gulbins, 2006; Zhang et al., 2007; Zeidan
Table 1 | Overview of stimuli inducing acid sphingomyelinase and/or
ceramide-enriched membrane platforms formation.
Stimulus References
PATHOGENS
Listeria monocytogenes Utermöhlen et al., 2003
Measles virus Gassert et al., 2009;
Avota et al., 2011
Mycobacterium avium Utermöhlen et al., 2008
Neisseria gonorrhoeae Grassmé et al., 1997;
Hauck et al., 2000
Pseudomonas aeruginosa Grassmé et al., 2003a;
Zhang et al., 2008
Rhinoviruses Grassmé et al., 2005;
Dreschers et al., 2007;
Miller et al., 2012
Salmonella typhimurium McCollister et al., 2007
Sindbis virus Jan et al., 2000
Staphylococcus aureus Esen et al., 2001
CLUSTER OF DIFFERENTIATION
MOLECULES
CD5 Simarro et al., 1999
CD14 Pfeiffer et al., 2001
CD20 Bezombes et al., 2004
CD28 Boucher et al., 1995
CD32 (FCγRII) Abdel Shakor et al., 2004;
Korzeniowski et al., 2007
CD38 Jia et al., 2008
CD40 Grassmé et al., 2002
CD95 Cifone et al., 1994;
Gulbins et al., 1995;
Cremesti et al., 2001;
Perrotta et al., 2010
CD95-DISC Kirschnek et al., 2000;
Grassmé et al., 2001a,b,
2003b
CD253 (TRAIL) Dumitru and Gulbins,
2006; Dumitru et al.,
2007; Li et al., 2013
IL-1 receptor Mathias et al., 1993
SOLUBLE MOLECULES
Platelet activating factor Samapati et al., 2012;
Predescu et al., 2013
Tumor necrosis factor Schütze et al., 1992,
1994; Garcia-Ruiz et al.,
2003; Edelmann et al.,
2011; Ardestani et al.,
2013
Visfatin Boini et al., 2010a
DRUGS AND OTHER STRESSES
Cisplatin Lacour et al., 2004;
Zeidan et al., 2008
Cu2+-treatment Lang et al., 2007
Doxorubicin Dumitru et al., 2007
Heat damage Chung et al., 2003
Ischemia-reperfusion injury Yu et al., 2000
Oxidative stress Zhang et al., 2007; Li
et al., 2012
(Continued)
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Table 1 | Continued
Oxygen radicals Scheel-Toellner et al.,
2004
UV-light Zhang et al., 2001;
Charruyer et al., 2005;
Kashkar et al., 2005;
Rotolo et al., 2005
γ-irradiation Santana et al., 1996;
Paris et al., 2001; Lee
et al., 2011
et al., 2008; Gassert et al., 2009; Perrotta et al., 2010; Avota
et al., 2011; Li et al., 2012, 2013). ASM generates ceramide by
hydrolyzing plasma membrane sphingomyelin molecules. The
generated ceramide molecules associate with each other, form-
ing microdomains. The merging of these small lipid clusters with
each other finally results in the formation of large, ceramide-
enriched membrane platforms (Grassmé et al., 2001a). The for-
mation of these platforms was shown in vivo (Grassmé et al.,
2001a) and in vitro (Holopainen et al., 1998). The in vitro
studies revealed that the generation of ceramide is sufficient
to trigger the formation of distinct platforms even in purely
artificial membranes without any cytoskeleton or other cellular
proteins (Holopainen et al., 1998) These platforms selectively
trap or exclude specific proteins for biophysical and energetic
reasons, and thus serve as a sorting unit for receptors and sig-
naling molecules (Grassmé et al., 2001a, 2003b) (Figure 1A).
Some ceramide-interacting proteins are already identified, for
instance kinase suppressor of Ras (KSR) (Zhang et al., 1997; Zhou
et al., 2002), ceramide-activated protein phosphatase (CAPP)
(Dobrowsky et al., 1993;Wolff et al., 1994; Saddoughi et al., 2013),
protein kinase C (PKC)-alpha, and -delta (Huwiler et al., 1998),
PKC-epsilon (Kashiwagi et al., 2002), PKC-zeta (Müller et al.,
1995), c-Raf-1 (Huwiler et al., 1996), phospholipase A2 (Huwiler
et al., 2001), cathepsin D (Heinrich et al., 1999), inhibitor 2 of
protein phosphatase 2A (I2PP2A) (Mukhopadhyay et al., 2009),
light chain 3 beta (LC3B-II) (Sentelle et al., 2012). Protein trap-
ping in or exclusion from rafts can facilitate and/or amplify
signaling processes. Via this mechanism, ceramide-enriched plat-
forms are involved in many cellular functions like apoptosis,
autophagy, inflammation, and senescence (reviewed in Gulbins
and Kolesnick, 2003; Gulbins and Li, 2006). Examples are
addressed in detail in the third part of this review, which discusses
ASM-related diseases. In an effort to treat ASM-related diseases,
inhibitors of ASM are necessary. One example for such an agent
is amitriptyline, an antidepressant drug.
AMITRIPTYLINE
Amitriptyline is a tricyclic antidepressant (TCA) that was initially
introduced by Merck in 1961 for the treatment of major depres-
sive disorder (Merck Sharp and Dohme, 1961). Till today this is
the only FDA (Food and Drug Administration)-approved indica-
tion, although amitriptyline is already used for a number of other
symptoms, including migraine prophylaxis (Mahloudji, 1969;
Gomersall and Stuart, 1973; Couch et al., 1976), neuropathic
pain disorders (Egbunike and Chaffee, 1990) and fibromyalgia
(Carette et al., 1986), nocturnal enuresis (Mishra et al., 1980) and
irritable bowel syndrome (Friedman, 1991). Anti-inflammatory
and antimicrobial properties of anti-depressive drugs have been
reported as well (Roumestan et al., 2007; Mandal et al., 2010).
Like other TCAs, amitriptyline is rapidly absorbed after oral
administration (Ziegler et al., 1978; Amsterdam et al., 1980;
Brunswick et al., 1980) and extensively metabolized on first-
pass through the liver, mainly by cytochrome P450 (CYP450)
oxidative enzymes (Bickel and Weder, 1968). N-demethylation
of amitriptyline yields nortriptyline, an anti-depressant in its
own right. Both amitriptyline and nortriptyline strongly bind to
plasma proteins (Borga et al., 1969) and exhibit extensive tissue
binding, evidenced by their high apparent volume of distribu-
tion (Schulz et al., 1983; Kornhuber et al., 1995; Lombardo et al.,
2004). Further metabolization by CYP450 upon hydroxylation
and glucoronidation results in inactivation followed by excretion
in the urine (Rudorfer and Potter, 1987; summarized in Gillman,
2007).
Initially, amitriptyline was described as a serotonin-
norepinephrine re-uptake inhibitor (Glowinski and Axelrod,
1964) which has a stronger action on serotonin transporters.
The metabolite nortriptyline is a more potent and selective
norepinephrine reuptake inhibitor (Tatsumi et al., 1997).
Additionally, amitriptyline was described to have antihis-
taminic and anticholinergic properties, because it functions as a
receptor-antagonist for a number of histamine and muscarinic
acetylcholine receptors (Owens et al., 1997). A number of
other receptors are also antagonized by amitriptyline (serotonin
receptors, α1-adrenergic receptor), whereas the drug is an
agonist for σ1-, TrkA-, and TrkB-receptors (Owens et al., 1997;
Jang et al., 2009). Numerous reports are published describing
amitriptyline to block different sodium, calcium, and potassium
channels (Schofield et al., 1981; Arita et al., 1987; Wooltorton and
Mathie, 1993; Pancrazio et al., 1998; Park et al., 1998; Punke and
Friederich, 2007). More importantly, amitriptyline is a functional
inhibitor of acid sphingoymelinase (Albouz et al., 1981; Hurwitz
et al., 1994b; Kornhuber et al., 2008). The enzyme resides in
the lysosome and is usually attached to the inner membrane
leaflet by electrostatic forces. Membrane-bound ASM is active
and degrades sphingomyelin, yielding ceramide. Administration
of antidepressants like amitriptyline or desipramine results in
lysosomal accumulation of the drugs (Kornhuber et al., 1995;
Daniel and Wojcikowski, 1997). This is due to the weak basicity
and high lipophilicity of the drugs, resulting in acid trapping in
the lysosome. Weak bases such as amitriptyline passively diffuse
across membranes in their neutral state. In acidic intracellular
compartments like the lysosome, they become protonated. In
this state, they can no longer cross the membrane and thus
are trapped inside of the compartment. The accumulation of
antidepressants in acidic compartments has been demonstrated
experimentally (Ishizaki et al., 1996) and is supported by a single-
cell stimulation model (Trapp et al., 2008). The accumulation of
antidepressants like amitriptyline or desipramine in the lysosome
interferes with the binding of ASM to the membrane, resulting
in detachment of ASM and subsequent inactivation by prote-
olytic degradation (Kölzer et al., 2004). The detached enzyme
is a target for intralysosomal proteases and is thus degraded
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FIGURE 1 | ASM-mediated platform formation and functional
inhibition of ASM. (A) ASM resides in the lysosome, where it is
anchored to the inner lysosomal membrane via electrostatic forces.
ASM activating stimuli result in a translocation of the enzyme from the
lysosome to the extracellular leaflet of the plasma membrane. There,
ASM generates ceramide from sphingomyelin. Due to the
self-association of ceramide molecules, ceramide-enriched microdomains
are formed. These lipid rafts fuse to large, ceramide-enriched platforms.
As a result of lipid-protein interactions, platform formation also results
in lateral sorting of proteins. Clustering of specific receptors (and
exclusion of others) serves to facilitate and/or amplify signaling
processes. (B) Functional inhibitors of acid sphingomyelinase (FIASMA)
like amitriptyline mediate the lysosomal degradation of ASM. Hence,
ASM activating stimuli can no longer induce a translocation of the
enzyme to the plasma membrane and the entire signaling cascade
downstream of ASM is lost upon amitriptyline treatment.
(Hurwitz et al., 1994b; for review see Kornhuber et al., 2014)
(Figures 1B, 2).
Weak basicity and high lipophilicity are physicochemical prop-
erties amitriptyline shares with other functional inhibitors of
acid sphingomyelinase (FIASMAs). These characteristics, rather
than specific structural motives, are the prerequisites for ASM
inhibition by these drugs (Kornhuber et al., 2008, 2011). The
observation that most antidepressants are also lipophilic weak
bases may thus explain why so many newly identified FIASMAs
are known antidepressants (see Table 2).
An interesting observation was made when using fendiline, a
FIASMA previously not known for its antidepressant properties:
the authors were able to demonstrate that fendiline had similar
antidepressant effects as amitriptyline in a mouse model of major
depression (Gulbins et al., 2013). The same study also showed
that the antidepressant effect of the tested drugs (amitriptyline,
fluoxetine and fendiline) was mediated by the Asm/ceramide sys-
tem, rather than by a direct effect on neurotransmitter reuptake,
leading to neuronal proliferation and survival (Gulbins et al.,
2013). It will be interesting to see if more antidepressants will
be shown to mediate their effect through ASM inhibition and
– on the other hand – if more FIASMAs will be shown to have
antidepressant effects.
APPLICATIONS OF AMITRIPTYLINE IN ASM-RELATED
DISEASES
Since amitriptyline is an efficient ASM inhibitor, it was used for
in vitro as well as in vivo studies to identify the impact of ASM in
different diseases. In this context, new roles of ASM and ceramide
in biological processes were identified.
ASM IN CARDIOVASCULAR AND METABOLIC DISEASE
One example for a newly identified role of ASM and ceramide
is platelet cell membrane scrambling and thrombus formation:
inhibition of ASMwith amitriptyline or genetic knock-out inhib-
ited platelet degranulation, phosphatidylserine exposure, and
thrombus formation (Münzer et al., 2014). The significance of
this, however, still needs further investigation.
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FIGURE 2 | Mechanisms of action of functional inhibitors of ASM.
FIASMA are weak bases and accumulate in acidic compartments like the
lysosome, because they become protonated at the acidic pH. Due to the
positive charge, they can then no longer cross the membrane (acidic
trapping). While the lipophilic moiety of the FIASMAs is anchored in the
lysosomal membrane, the protonated, positively charged portion is exposed
to the lumen, thus altering the electrostatic properties of the inner lysosomal
membrane. As a result, the electrostatic adherence of ASM to the
membrane is lost. Luminal ASM is inactive and targeted by intralysosomal
proteases for proteolytic degradation.
Using human cardiac biopsies, Usta et al. (2011) were able
to demonstrate that ceramide formation is involved in car-
diomyocyte apoptosis, which can occur during cardioplegia
and reperfusion. Subjection of the biopsy samples to different
cycles of cardioplegia (characterized by blocked perfusion and
oxygen supply) and reperfusion ex vivo resulted in cardiomy-
ocyte apoptosis in the untreated group. In the amitriptyline-
treated samples, apoptosis was significantly reduced. These results
suggest that amitriptyline could have a protective effect in
ischemia/reperfusion injury in a clinical setting.
According to studies concerning obesity and kidney damage,
adipokines (cytokines, which are highly expressed by adipose
tissue) mediate the clustering of lipid rafts in glomerular endothe-
lial cells. One adipokine, visfatin, was found to activate ASM,
leading to ceramide production and NADPH oxidase activation,
thus resulting in increased oxidative stress (Boini et al., 2010a;
Xia et al., 2011). This causes disruption of the microtubular
network and permeability of the endothelial cell layer (Boini
et al., 2010a). Amitriptyline treatment of glomerular endothe-
lial cells not only blocked the formation of ceramide-enriched
membrane platforms and release of reactive oxygen species, but
also protected the cells from the disruption of the microtubu-
lar network – an important aspect of kidney damage (Boini
et al., 2010a). These in vitro results were verified in vivo: anal-
ysis of mice on high fat diet revealed elevated ceramide plasma
levels, increased adipose tissue Asm activity and higher glomeru-
lar damage index (Boini et al., 2010b). Treatment of mice with
amitriptyline normalized Asm activity and the plasma ceramide
level and protected – at least in part – from cell damage in the
kidney. Further analysis showed a faster glucose uptake from the
plasma in the amitriptyline-treated group (Boini et al., 2010b).
In conclusion, these results indicate that treatment of obesity or
metabolic syndrome with amitriptyline could have a protective
effect on glomeruli and kidney function.
Ceramide has been implicated to be involved in the pathogene-
sis of diabetes by mediating beta-cell apoptosis, insulin resistance
and insulin synthesis (for review see Galadari et al., 2013). For
instance, an increase of skeletal muscle ceramide was observed
in obese men with risk for type 2 diabetes and was inversely
related to insulin sensitivity (Straczkowski et al., 2007). The role
of ASM in diabetes, on the other hand, is not well defined.
It was demonstrated that patients with diabetes type 2 show
elevated plasma levels of the Zn2+-dependent secretory ASM
(Gorska et al., 2003) and incubation of rat hepatocytes with
ceramide or ASM resulted in the phosphorylation of insulin
receptor substrate (IRS-1) leading to blocked insulin signaling
and thereby insulin resistance (Herschkovitz et al., 2007). In
addition, some common diabetic complications were shown to
involve ASM. For instance, ASM was implicated in atheroscle-
rosis (Devlin et al., 2008) and diabetic retinopathy (Opreanu
et al., 2010, 2011). Although the mechanism of ASM action in
diabetes is not completely investigated FIASMAs are attractive
new treatment options for diabetes or at least for these diabetic
complications.
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Table 2 | Tricyclic antidepressants (TCA) and their role as functional
inhibitors of acid sphingomyelinase (FIASMA).
TCA (brand name) FIASMA
Amineptine (Survector) ?
Amitriptyline (Elavil) yes
Amitripylinoxide (Amioxid) ?
Amoxapine (Ascendin) ?
Butriptyline (Evadyne) ?
Clomipramine (Anafranil) yes
Demexiptiline ?
Desipramine (Norpramin) yes
Dibenzepin (Noveril) ?
Dimetacrine (Istonil) ?
Dosulepin (Prothiaden) ?
Doxepine (Sinequan) yes
Imipramine (Tofranil) yes
Imipraminoxide (Elepsin) ?
Iprindole (Prondol) ?
Lofepramine (Gamanil) yes
Melitracen (Adaptol) ?
Metapramine (Timaxel) ?
Nitroxazepine (Sintamil) ?
Nortriptyline (Aventyl) yes
Noxiptiline (Agedal) ?
Pipofezine (Azafen) ?
Propizepine (Depressin) ?
Protriptyline (Vivactil) yes
Quinupramine (Kinupril) ?
Tianeptine (Coaxil) ?
Trimipramine (Surmontil) yes
References: (Kornhuber et al., 2008, 2011).
? = ASM-inhibitory capacity is not yet tested.
ASM IN IMMUNE CELL FUNCTION AND INFLAMMATORY DISEASES
Xuan and coworkers used amitriptyline to investigate the role
of the ASM/ceramide system for the effects of thymol and xan-
thohumol on the immune system. Thymol is known to have
antimicrobial activity (Guo et al., 2009) and xanthohumol was
described to have an anticancer effect (Cho et al., 2008). Both
studies revealed that incubation of dendritic cells with one
of the two chemicals led to ASM activation, ceramide forma-
tion and induction of apoptosis by caspase-8 and -3 activation.
Thymol- and xanthohumol-induced apoptosis was blocked in
ASM-deficient-, as well as in amitriptyline-treated dendritic cells,
indicating that ASM and ceramide are crucial for the thymol- and
xanthohumol-induced signaling cascade (Xuan et al., 2010a,b).
Dendritic cells were also shown to be sensitive for amyloid-β-
peptide- (Aβ1–42) and islet amyloid polypeptide (IAPP) induced
cell death. Incubation of isolated dendritic cells with these pep-
tides induced ASM activation and ceramide formation, resulting
in induction of apoptosis. Pre-incubation of dendritic cells with
amitriptyline abrogated this process (Xuan et al., 2010c). These
results point to ASM as possible therapeutic target for amyloid-
related disease (e.g., Alzheimer’s disease) and further studies have
to clarify if amitriptyline or analogs can be used to treat these
diseases – or at least to ameliorate their symptoms.
With regard to the immune system, Yang and coworkers inves-
tigated the role of ASM in mast cell function (Yang et al., 2014).
Isolated mast cells from wild type mice or Asm knock-out mice
were stimulated with antigens, resulting in a rapid increase of
Asm activity in wild type cells, combined with intracellular Ca2+
release, activation of K+-channels and antigen-induced migra-
tion. These effects were abolished or reduced in mast cells from
Asm knock-out mice. The reaction of amitriptyline-treated cells
to the tested antigens was similar to Asm knock-out cells (Yang
et al., 2014). Hence, Asm seems to have an important role in mast
cell function and inhibitors of Asm, like amitriptyline, may be
potential new anti-allergic agents.
The impact of ceramide on inflammatory bowel disease has
also been demonstrated. Analysis of mice with induced chronic
colitis revealed an increase of ceramide combined with induc-
tion of matrix metalloproteinase 1 (MMP-1) by cytokines like
TNF-α and IL-1β (Bauer et al., 2009). Treatment of mice with
imipramine, another functional inhibitor of ASM, resulted in
blocked MMP-1 induction (Bauer et al., 2009). Because MMP-
1 is correlated with destruction of intestinal tissue, the blockage
of activation by antidepressants like imipramine or amitriptyline
could be a potential therapeutic approach for inflammatory bowel
disease.
ASM IN LIVER DISEASES
ASM and ceramide were also investigated in Cu2+ induced hep-
atic failure (Wilson disease). In this case, the accumulation of
Cu2+ was shown to activate ASM. The subsequent ceramide
release induced apoptosis of liver cells and formation of cirrhosis
(Lang et al., 2007). In a rat model of Wilson disease, amitripty-
line treatment protected the animals from cirrhosis, liver failure
and early death. Another feature of Wilson disease is anemia.
Ceramide was shown to induce the exposure of phosphatidylser-
ine at the plasma membrane of erythrocytes, leading to rapid
internalization of the erythrocytes by other cells, thus resulting in
anemia. Hence, the authors suggest that pharmacological block-
age of ASMmay be an effective therapy inWilson disease patients
to protect liver cell death as well as against anemia (Lang et al.,
2007).
In terms of hepatic disease, it was also recently demonstrated
that Asm inhibition by amitriptyline reduces hepatic fibrosis in
mice (Quillin et al., 2014). The authors were able to show that
treated mice had significantly less collagen deposits and less acti-
vated hepatic stellate cells and an improved hepatic architecture.
Thereby it can be concluded that amitriptyline could be an effi-
cient medication for liver fibrosis. Furthermore, a new study by
Grammatikos and colleagues show that serum ASM level is signif-
icantly upregulated in patients suffering from chronic hepatitis C
virus infection or non-alcoholic fatty liver disease (Grammatikos
et al., 2014). However, the potential of ASM as a therapeutic target
in these diseases has not yet been investigated.
ASM IN MAJOR DEPRESSION
The role of ASMhas been extensively studied inmajor depression.
Blood samples from depressed patients exhibited an increased
ASM activity in comparison to samples from healthy control
subjects. Treatment of peripheral blood mononuclear cells with
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amitriptyline or imipramine reduced ASM activity and the effect
lasted for several days (Kornhuber et al., 2005). Further analysis of
the role of ceramide in major depression revealed that amitripty-
line and fluoxetine, also a functional inhibitor of ASM, reduce
ceramide levels in the hippocampus of mice in a stress-induced
depression model. This effect was combined with increased neu-
rogenesis, neuronal maturation and survival of neurons in the
hippocampus, as well as normalized behavior (Gulbins et al.,
2013). The impact of the ASM/ceramide-system as a potential
therapeutic target for the treatment of depressions was recently
summarized by Kornhuber et al. (2014). According to their
hypothesis, ceramide is formed as a result of stress or infection
in the periphery or in the brain itself; causing different effects,
e.g., increase of oxidative stress or release of proinflammatory
cytokines, and thereby ceramide blocks hippocampal neurogene-
sis. Reducing ceramide levels should therefore be an efficient way
to improve both mood and health in depressed patients.
ASM IN CANCER
Lysosomal cell death programs are attractive in cancer therapy
because cancer cell lysosomes are less stable than normal lyso-
somes (Fehrenbacher et al., 2004) and they offer options to
circumvent therapy resistance due to defective apoptosis signal-
ing and multi-drug resistance (reviewed in Cesen et al., 2012;
Groth-Pedersen and Jäättelä, 2013). In 2013, Peterson and col-
leagues demonstrated that inhibition of ASM selectively desta-
bilizes cancer cell lysosomes, triggers cancer-specific lysosomal
cell death, reduces tumor growth in vivo and reverts multidrug
resistance (Petersen et al., 2013). Cancer selectivity was associated
with a transformation-associated reduction in ASM expression
in the tested cells. Cancer cells failed to maintain sphingomyelin
hydrolysis during drug exposure to ASM-inhibitors, resulting in
lysosomal destabilization due to sphingomyelin accumulation.
Hence, some studies have already investigated the effect of ASM-
overexpression or use of recombinant acid sphingomyelinase
as an adjuvant to conventional chemotherapeutic agents with
promising results (Grammatikos et al., 2007; Osawa et al., 2013;
Savic et al., 2013). On the other hand a combinatory strategy of
ASM inhibition together with conventional chemotherapeutics
and/or irradiation could be detrimental, as a number of stud-
ies indicate that several chemotherapeutic drugs (Tepper et al.,
1999; Lacour et al., 2004; Dumitru et al., 2009a,b) and irradia-
tion (Santana et al., 1996; Paris et al., 2001; Garcia-Barros et al.,
2003, 2010; Lee et al., 2011) mediate cell death via ASM activation
and ceramide formation. Given these contrasting treatment con-
cepts, it remains to be investigated whether ASM inhibitors can
be successfully established as anti-cancer therapeutics.
ASM IN INFECTIOUS DISEASES
Ceramide also plays a role in bacterial and viral infections, but
also in infectious diseases caused by parasites like Plasmodia.
In 2008, Brand and coworkers demonstrated that Plasmodia
require ASM for infection of erythrocytes (Brand et al., 2008).
Amitriptyline treatment delayed the increase in parasitemia both
in in vitro and in vivo experiments. Nonetheless, genetic knock-
out of Asm in mice did not prolong survival after infection. This
might be explained by the finding that Plasmodium has its own
sphingomyelinase activity and is thus independent of the host’s
enzyme (Hanada et al., 2002). Brand and coworkers concluded
that pharmacological inhibition of ASM by amitriptyline might
be a potential strategy to treat malaria, because amitriptyline
blocks both parasite- and host sphingomyelinase activity (Brand
et al., 2008).
Grassmé and colleagues demonstrated that infection of epithe-
lial cells by rhinoviruses trigger rapid activation and translocation
of ASM to the plasma membrane, resulting in the formation
of ceramide-enriched membrane platforms, to which rhinovirus
then locates (Grassmé et al., 2005). Blockage of ceramide genera-
tion by amitriptyline or imipramine, as well as genetic knock-out
of Asm prevented rhinovirus infection (Grassmé et al., 2005).
Similarly, imipramine was used to investigate the importance
of the ASM/ceramide system for ebolavirus infection (Miller
et al., 2012). This study demonstrated that virus-like particle
require plasma membrane ASM and blockage of ASM inhibited
the infection with ebolavirus. Likewise, measles virus (MV) was
shown to activate ASM in dendritic cells by ligation of a pat-
tern recognition receptor called DC-SIGN (Avota et al., 2011).
DC-SIGN-dependent ASM activation and subsequent formation
of ceramide-enriched membrane domains promote the recruit-
ment and clustering of CD150, the uptake receptor for MV, thus
promoting virus uptake (Avota et al., 2011). Moreover, an ear-
lier study with MV in T cells demonstrated that accumulation
of ceramides in response to MV interfered with the formation
of membrane protrusions, T cell spreading, front/rear polariza-
tion, and chemokine-induced T cell motility (Gassert et al., 2009).
Amitriptyline-treatment rescued lymphocyte cytoskeletal reorga-
nization and thus restored T cell activation and function (Gassert
et al., 2009).
In terms of bacterial infections, ASM has a crucial role in
infections with a number of pathogens, e.g., S. aureus, L. mono-
cytogenes, P. aeruginosa, S. thyphimurium, E. coli, and M. avium
(for review see Grassmé and Becker, 2013). Ceramide-enriched
membrane domains were shown to be required for the internal-
ization of P. aeruginosa, the induction of death in infected cells
and the controlled release of cytokines (Grassmé et al., 2003a).
Asm-deficient mice are highly susceptible to pulmonary P. aerug-
inosa infections and infected mice die from sepsis because they
are unable to clear the infection (Grassmé et al., 2003a). Similarly,
Asm-deficientmice are also highly susceptible to L. monocytogenes
infections (Utermöhlen et al., 2003): this bacterium is taken up by
macrophages and subsequently killed by phagolysosomal fusion.
Asm-deficiency prevents this (Schramm et al., 2008; Utermöhlen
et al., 2008), enabling the pathogen to escape from the phago-
some, replicate in the cytoplasm and spread from cell to cell unaf-
fected by the humoral immune response (Portnoy et al., 1988;
Cossart et al., 1989; Goldfine and Wadsworth, 2002; Schnupf
and Portnoy, 2007). Furthermore, ASM is also important for the
killing of S. typhimurium by macrophages via NADPH-mediated
release of ROS (McCollister et al., 2007). Therefore, ASM-
deficient macrophages were less capable of killing S. typhimurium
than wildtype cells (McCollister et al., 2007).
The opportunistic pathogen, E. coli can cause infectious dis-
eases, including sepsis. Falcone and coworkers demonstrated
that ASM-dependent apoptosis of immature dendritic cells in
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response to E. coli contributes to the development of sepsis.
ASM inhibition by imipramine prevented dendritic cell apopto-
sis (Falcone et al., 2004). Next to dendritic cells, endothelial cell
apoptosis is a crucial event in LPS-induced endotoxic shock syn-
drome and ASM was shown to mediate this process (Haimowitz-
Friedman et al., 1997). Hence, Asm-deficient mice were protected
against LPS-induced endothelial cell apoptosis and thus sur-
vived endotoxic shock syndrome (Haimowitz-Friedman et al.,
1997). Another example are pathogenic mycobacteria. This class
of bacteria typically infects and replicates within macrophages
(Oh et al., 1996; Russel, 2001). In infected tissues, the infected
macrophages become organized in granulomas together with cer-
tain other cells (Russel, 2007). Tissues of Asm-deficient mice
infected with M. avium contain only small, delimited granulo-
mas and Asm-deficient mice are more resistant to lethal infec-
tions with M. avium than wild type mice (Utermöhlen et al.,
2008).
ASM IN CYSTIC FIBROSIS AND LUNG INJURY
Bacterial infections also play an important role in the progression
of cystic fibrosis (CF). The disease is caused by a genetic defect in
the cystic fibrosis transmembrane conductance regulator (CFTR)
gene and affects different organs, especially the lungs. Key fea-
tures of CF lung disease are chronic lung inflammation, recurrent
and chronic lung infections and pulmonary fibrosis. Both ASM
and acid ceramidase were suggested to be dysregulated in CF.
As a result ceramide is extensively generated and accumulates in
the lungs of patients. In a mouse model, amitriptyline treatment
or partial knock-out of Asm prevented the pathological find-
ings of CF (Teichgräber et al., 2008). Additionally, the ceramide
content of bronchial epithelial cells was normalized after inhala-
tion of CF mice with different antidepressants, e.g., amitriptyline,
trimipramine, desipramine, fluoxetine, amlodipine, chlorproth-
ixene, or sertraline. Inhibition of Asm also prevented P. aeruginosa
infection and reduced lung inflammation in CF mice (Becker
et al., 2010a). Moreover, amitriptyline treatment also normal-
ized ceramide levels, cell death rates and cytokine release in other
tissues affected by CF, e.g., trachea and intestine (Becker et al.,
2010b). Recently, it was also shown that ceramide mediates the
development of pulmonary fibrosis in CF and that prolonged
amitriptyline treatment is able to lessen fibrosis development
and to reduce pulmonary inflammatory cytokines (Ziobro et al.,
2013).
As a result of these findings, clinical trials were conducted
with amitriptyline as a potential medication for CF. In a first
randomized cross-over pilot study 4 adult CF patients received
amitriptyline for 14 days. This study was followed by a phase IIa
study with 19 adult CF patients, who were treated with amitripty-
line for 28 days. Amitriptyline was well tolerated in these studies
and the treatment significantly improved respiratory function of
the patients (Riethmüller et al., 2009). In a subsequent phase IIb
randomized, double-blind, and placebo-controlled study, 21 CF
patients were treated with amitriptyline for 28 days and compared
to 19 patients receiving placebo. Again, an increase of lung func-
tion was detected, as well as a decrease of ceramide levels. Safety
analysis revealed that amitriptyline did not have any severe effects
(Nährlich et al., 2013).
Concerning another inflammatory respiratory condition, Asm
was shown to be elevated in a model of acute inflamma-
tory lung disease in neonates (Von Bismarck et al., 2008). The
authors hypothesized that Asmmay inactivate surfactant and pro-
mote proinflammatory responses and thus added imipramine
to the surfactant preparation to stabilize it. The addition of
imipramine to the exogenous surfactant improved lung function
and decreased leukocyte counts and interleukin concentrations
in the lavage fluid (Von Bismarck et al., 2008). In a follow-up
study, Preuss and co-workers also demonstrated that topical Asm
inhibition by imipramine significantly improves several respira-
tory parameters and lung edema in a triple-hit lung injury model
(Preuss et al., 2012). Taken together, these studies make a strong
argument for the use of surfactant preparations fortified with an
ASM inhibitor for the treatment of neonates with hypoxemic res-
piratory failure. Additionally, a key player in acute lung injury,
platelet-activating factor (PAF) mediates the activation of ASM
and the formation of ceramide, resulting in the development of
pulmonary edema. Inhibition of Asm by imipramine resulted in a
significant reduction of PAF-induced edema in perfused rat lungs
(Göggel et al., 2004). Further analysis of the PAF-induced signal-
ing pathway revealed that caveolin-1 is enriched in caveolae of
endothelial cells upon ASM activation (Yang et al., 2010). This
leads to a decrease of endothelial NO (eNO) formation, which
is necessary for the regulation of vascular permeability leading
to the formation of pulmonary edema. Pharmacological inhibi-
tion of Asm by imipramine blocked PAF-induced decrease of eNO
and edema formation (Yang et al., 2010). These results demon-
strate a therapeutic approach of ASM-inhibiting drugs to prevent
pulmonary edema and acute lung injury.
FUTURE PERSPECTIVE
Historically, amitriptyline has been employed in the clinic and
in research because of its known antidepressant properties. More
recently amitriptyline has been investigated because of its capac-
ity to inhibit ASM. In summary, these in vivo studies revealed that
amitriptyline is a candidate for the treatment of bacterial and viral
infections, cystic fibrosis, protection from kidney damage, ame-
lioration of liver cirrhosis and fibrosis and suppression of allergic
reactions. An additional, large body of in vitro studies expands
the potential indications even further – including for instance
also Alzheimer’s disease. This demonstrates the vast potential of
existing drugs for other clinical applications.
Despite the exciting new possibilities for the use of ASM
inhibitors, the balance between too much ASM activity and too
little (or no) ASM activity is sensitive. One example underlin-
ing this is the increased death rate of Asm knock-out mice as a
result of bacterial infection, because the bacteria cannot be phago-
cytosed and killed (Utermöhlen et al., 2003). Another example
is thrombus formation due to too little ASM activity in plasma
(Münzer et al., 2014). Excessive inhibition of ASMwould result in
Niemann-Pick disease-like symptoms, whereas insufficient inhi-
bition will result in failure to treat the specific, ASM-related
disease. Thus, amitriptyline and all other ASM inhibitors have to
be handled with care.
A further reason for caution is the concern about the safety
of TCAs like amitriptyline. Due to these concerns, amitriptyline
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is no longer considered a first-line therapy in depression—even
though amitriptyline is at least as effective—if not more—than
other antidepressants (Guaiana et al., 2007). TCAs have a wide
range of side effects, mostly related to their antimuscarinic prop-
erties, e.g., dry mouth, blurred vision, constipation, drowsiness,
and dizziness (Potter et al., 2006). Thus, they are often poorly
tolerated by patients. Additionally, TCAs have a narrow thera-
peutic window. To be effective, plasma concentrations of 50–
300 ng/ml are required, but toxicity effects start at approximately
450 ng/ml, with major toxicity occurring above 1000 ng/ml and
death at about 2000–3000 ng/ml (Schulz and Schmoldt, 2003;
Amitai and Frischer, 2004, 2006). The toxic effects are due to ion
channel blockade, which results in disruption of cardiac conduc-
tion (Marmo et al., 1972). The narrow therapeutic window is a
risk in the treatment of depressed patients: amitriptyline, along
with other TCAs, is the leading vehicle for completed suicide
attempts, accounting for 82% of deaths by antidepressant poison-
ing. Thus, the continued use as antidepressants has been seriously
questioned (Montgomery, 1997).
However, patients suffering fromASM-related diseases that are
currently investigated as new amitriptyline targets are not at a
higher risk for suicide than the general population. Also, pre-
liminary studies suggest that treatment of these conditions with
amitriptyline may require lower doses of the drug than necessary
for the treatment of depression and that amitriptyline is also well
tolerated at these lower dosages (Riethmüller et al., 2009; Nährlich
et al., 2013).
Nevertheless, amitriptyline could potentially also be replaced
by other drugs in the treatment of ASM-related diseases. The
analysis of further antidepressant drugs tested for their abil-
ity to block ASM revealed that other existing drugs are also
ASM inhibitors (see Table 2). The search for more inhibitors
that specifically block ASM was summarized by Kornhuber et al.
(2010). They called this new group of ASM inhibitors FIASMA
(Kornhuber et al., 2010). Most of the newly identified FIASMAs
are already licensed for the use in humans and are potential alter-
natives to amitriptyline. The reason why amitriptyline is currently
the most widely investigated FIASMA for the treatment of dis-
eases with a deregulation in the ASM/ceramide system is probably
that it is the best-known candidate and has been used in the clinic
the longest. Moreover, it is easily available and relatively cheap.
There is, however, no reason to assume that amitriptyline could
not be exchanged in favor of another FIASMA and/or another
TCA with better tolerability and safety, should it prove trou-
blesome for one of the new indications in the future. Similarly,
future investigations may reveal that other drugs are more effi-
cient or effective than amitriptyline for the treatment of these
diseases. For now, however, amitriptyline is a cheap and safe drug
with the potential to treat patients suffering from ASM-related
disease.
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